Supplementary Figures from Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies

Figure S1: Sorafenib treatment induces phospho-ERK rebound in 32D/ITD cells. Figure S2: Further characterization of FLT3 inhibitor-mediated signaling adaptation. Figure S3: FLT3 signaling is maintained in low serum conditions. Figure S4: MEK inhibitor treatment abrogates phospho-ERK rebound. Figure S5: MEK inhibition synergizes with FLT3 inhibition to increase apoptosis in FLT3/ITD AML. Figure S6: NRAS mutant AML is sensitive to MEK inhibition but insensitive to the addition of sorafenib. Figure S7: MEK inhibition sensitizes K562 but does not sensitize PC9 or SKBR3 cells to RTK inhibition.